{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:11:55Z","timestamp":1777266715481,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703014"],"award-info":[{"award-number":["81703014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Program","doi-asserted-by":"publisher","award":["20YDTPJC00950"],"award-info":[{"award-number":["20YDTPJC00950"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejmech.2023.115510","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:33:55Z","timestamp":1685406835000},"page":"115510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-1111","authenticated-orcid":false,"given":"Cen","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangsun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Chuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2023.115510_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115510_bib2","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease[J]","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115510_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8507583","article-title":"Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease","volume":"2019","author":"Aragon\u00e8s","year":"2019","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115510_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease[J]","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115510_bib6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease[J]","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease[J]","volume":"15","author":"Neuschwander-Tetri","year":"2017","journal-title":"BMC Med."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115510_bib8","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3390\/ijms20112841","article-title":"NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management[J]","volume":"20","author":"Lonardo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ncp.10449","article-title":"Evolution of NAFLD and its management[J]","volume":"35","author":"Mundi","year":"2020","journal-title":"Nutr. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115510_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115510_bib12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/medicina57080822","article-title":"Phytotherapy as multi-hit therapy to confront the multiple pathophysiology in non-alcoholic fatty liver disease: a systematic review of experimental interventions","volume":"57","author":"Ore","year":"2021","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/jhep.2002.30690","article-title":"Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association[J]","volume":"35","author":"Pagano","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115510_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease[J]","volume":"149","author":"du Plessis","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-2006-960170","article-title":"Genetics of alcoholic and nonalcoholic fatty liver disease","volume":"27","author":"Anstee","year":"2007","journal-title":"Semin. Liver. Dis."},{"issue":"15","key":"10.1016\/j.ejmech.2023.115510_bib16","article-title":"Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).[J]","volume":"19","author":"Christine","year":"2013","journal-title":"Curr. Pharm. Design."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2015.03.032","article-title":"Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts[J]","volume":"63","author":"Ma","year":"2015","journal-title":"J. Hepatol.."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115510_bib18","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Luca","year":"2009","journal-title":"J. Hepatol. (Baltimore, Md.)"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice[J]","volume":"233","author":"Derosa","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115510_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator\u2013activated receptors as transcriptional nodal points and therapeutic targets[J]","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs[J]","volume":"51","author":"Kota","year":"2005","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115510_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1194\/jlr.M077941","article-title":"Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate[J]","volume":"58","author":"Rajamoorthi","year":"2017","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115510_bib23","first-page":"604","article-title":"Elafibranor for the treatment of NAFLD: one pill, two molecular targets and multiple effects in a complex phenotype[J]","volume":"15","author":"Sookoian","year":"2016","journal-title":"Ann. Hepatol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.2015.1006359","article-title":"Early investigational drugs targeting PPAR-\u03b1 for the treatment of metabolic disease[J]","volume":"24","author":"Liu","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115510_bib25","author":"ClinicalTrials"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115510_bib27","series-title":"Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis[EB\/OL","author":"ClinicalTrials","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115510_bib28","series-title":"Genfit's elafibranor en route to NASH graveyard with phase 3 flop[EB\/OL","author":"Idrus","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115510_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ejmech.2018.07.032","article-title":"Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation[J]","volume":"156","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115510_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ecoenv.2018.12.096","article-title":"Size-dependent cytotoxicity study of ZnO nanoparticles in HepG2 cells[J]","volume":"171","author":"Chen","year":"2019","journal-title":"Ecotox. Environ. Safe."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115510_bib31","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3748\/wjg.v25.i24.3009","article-title":"Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease[J]","volume":"25","author":"Mato","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib32","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content[J]","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep-UK."},{"key":"10.1016\/j.ejmech.2023.115510_bib33","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.biopha.2017.11.083","article-title":"Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation[J]","volume":"96","author":"Xiong","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115510_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103963","article-title":"Design, synthesis, and biological evaluation of novel dual PPAR\u03b1\/\u03b4 agonists for the treatment of T2DM[J]","volume":"101","author":"Ren","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115510_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113417","article-title":"Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities[J]","volume":"219","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl 6","key":"10.1016\/j.ejmech.2023.115510_bib37","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury[J]","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jgh.13814","article-title":"Fatty liver index andhepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes[J]","volume":"33","author":"Svikl\u0101ne","year":"2018","journal-title":"J Gastroen Hepatol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115510_bib39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease[J]","volume":"368","author":"Choi","year":"2013","journal-title":"New Engl J Med."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115510_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOL.0b013e3283544956","article-title":"Determinants of VLDL-triglycerides production[J]","volume":"23","author":"Nielsen","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00281-019-00754-3","article-title":"Molecular determinants for the polarization of macrophage and osteoclast[J]","volume":"41","author":"Yang","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115510_bib42","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","article-title":"The role of cholesterol in cancer[J]","volume":"76","author":"Kuzu","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115510_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01457-1","article-title":"LDL\/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study[J]","volume":"20","author":"Zou","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejmech.2023.115510_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J]","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115510_bib46","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","article-title":"Glutathione synthesis[J]","volume":"1830","author":"Lu","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115510_bib47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jmf.2017.4080","article-title":"Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: a randomized, double-blind controlled trial[J]","volume":"21","author":"Bumrungpert","year":"2018","journal-title":"J. Med. Food"},{"key":"10.1016\/j.ejmech.2023.115510_bib48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.freeradbiomed.2020.10.027","article-title":"Plasma GSH levels and Alzheimer's disease. A prospective approach.: results from the HELIAD study[J]","volume":"162","author":"Charisis","year":"2021","journal-title":"Free Radical Bio Med"},{"key":"10.1016\/j.ejmech.2023.115510_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson's disease[J]","volume":"62","author":"Smeyne","year":"2013","journal-title":"FREE RADICAL BIO MED"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2007.11.004","article-title":"Inhibition of murine AIDS by pro-glutathione (GSH) molecules[J]","volume":"77","author":"Fraternale","year":"2008","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115510_bib51","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1083\/jcb.201804161","article-title":"Glutathione metabolism in cancer progression and treatment resistance[J]","volume":"217","author":"Bansal","year":"2018","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115510_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health[J]","volume":"134","author":"Wu","year":"2004","journal-title":"J. Nutr."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115510_bib53","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation[J]","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur. J. Sport Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) \u2013 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters[J]","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115510_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-020-00691-6","article-title":"Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2[J]","volume":"9","author":"Zhang","year":"2020","journal-title":"Infect Dis Poverty."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115510_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106012","article-title":"Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking[J]","volume":"56","author":"Yu","year":"2020","journal-title":"Int J Antimicrob Ag"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423004762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423004762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T14:52:46Z","timestamp":1730991166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423004762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"alternative-id":["S0223523423004762"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115510","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115510"}}